Featured Research

from universities, journals, and other organizations

Molecular mechanisms offer hope for new pain treatments

Date:
August 5, 2011
Source:
University of Montreal
Summary:
By working with individuals suffering from a severe disorder that causes sensory neurons to degenerate, researchers have discovered how a specific genetic mutation causes their patients' condition, which in turn has revealed more information about the mechanisms in our bodies which enable us to sense pain.

By working with individuals suffering from a severe disorder that causes sensory neurons to degenerate, researchers at the University of Montreal Hospital and CHU Sainte-Justine Hospital have discovered how a specific genetic mutation causes their patients' condition, which in turn has revealed more information about the mechanisms in our bodies which enable us to sense pain. Genetic mutations are mistakes in our genetic code that can either be passed from parents to their children or created when DNA is replicated.

Lead author Dr. Jean-Baptiste Rivi่re published the team's results in the American Journal of Human Genetics August 4.

The currently untreatable disorder is called "hereditary sensory and autonomic neuropathy type II." It starts during early childhood and is characterized by a loss of perception of pain, touch and heat. Because affected individuals are unable to react to pain and protect themselves, they often develop ulcers that can become infected, leading to amputation of the affected body part. By working with their international colleagues under the direction of the University of Montreal's Dr. Guy Rouleau, the research team was able to pinpoint how the disorder is related to the patients' genetic code.

"After showing that the WNK1/HSN2 protein interacts with the KIF1A gene, we were able to go back to the cohort of patients and identify mutations of the KIF1A gene," Rivi่re said. "The study results will be of immediate benefit to HSAN2 patients, as the identification of this new gene has made it possible to provide valuable genetic testing to assess the risk or the cause of the disease in individuals at risk or presenting the disease." While the genetic mutation affects very few people, the knowledge that the researchers have gained is applicable to everyone. Scientists know the different parts of our genetic code, but they don't know how every single specific gene contributes to the functioning of our bodies. When a gene does not function properly due to a mutation, the resulting disorder can provide insight into its normal role. These findings provide clues about the components underlying the transmission of pain signal from sites of injury to the central nervous system

Researchers may be able to use their new knowledge about the KIF1A gene to develop new pain relief drugs. "Our results not only open the door to a better understanding of this disorder," Rouleau explained, "they also give us valuable information about the molecular mechanisms involved in pain perception, which is important for the development of new anti-pain drugs." A future drug might work by modulating interactions between different proteins associated with pain and KIF1A. "Further research could help us to identify other proteins that are transported by KIF1A or that interact with it, and that will help to better refine our understanding of pain mechanisms," noted Dr. Patrick Dion, who also contributed to the research.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Baptiste Rivi่re et al. KIF1A, an Axonal Transporter of Synaptic Vesicles, Is Mutated in Hereditary Sensory and Autonomic Neuropathy Type 2. American Journal of Human Genetics, 4 August 2011 DOI: 10.1016/j.ajhg.2011.06.013

Cite This Page:

University of Montreal. "Molecular mechanisms offer hope for new pain treatments." ScienceDaily. ScienceDaily, 5 August 2011. <www.sciencedaily.com/releases/2011/08/110804123913.htm>.
University of Montreal. (2011, August 5). Molecular mechanisms offer hope for new pain treatments. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/08/110804123913.htm
University of Montreal. "Molecular mechanisms offer hope for new pain treatments." ScienceDaily. www.sciencedaily.com/releases/2011/08/110804123913.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins